At an FDA public meeting on issues and challenges around risk evaluation and mitigation strategy (REMS), the AAFP urged the agency to keep REMS-specific CME for extended-release and long-acting opioids voluntary, reported AAFP News Now.
Ann Karty, MD, medical director of the AAFP division of CME, said a prescriber-education mandate could impact patient access to those drugs.
It could also create confusion for doctors who are licensed in multiple states.
“If you start adding more requirements… there is the potential that some will not participate,” Karty told AAFP News Now.
From the September 01, 2013 Issue of MM+M - Medical Marketing and Media
